



HEALTH MONITORING UNIT

MINISTRY OF HEALTH
OF THE REPUBLIC OF CYPRUS

CYPRUS CANCER REGISTRY

Cyprus Cancer Cases
Trachea, Bronchus and Lung
1998-2015


Anna Demetriou
Health Monitoring Unit
Ministry of Health
Cyprus

Τηλ: 22605390
Email: ADemetriou@moh.gov.cy
Φαξ: 22605527



**Number of C33-C34 (Trachea, Bronchus and Lung)
Cancer Cases by year and sex, 1998-2015***

	Male	Female	Total
1998	90	19	109
1999	107	27	134
2000	118	26	144
2001	144	29	173
2002	140	37	177
2003	137	24	161
2004	144	45	189
2005	146	42	188
2006	140	57	197
2007	163	45	208
2008	189	61	250
2009	218	62	280
2010	211	59	270
2011	240	71	311
2012	228	59	287
2013	264	68	332
2014	254	65	319
2015	243	81	324
Total	3176	877	4053



*Excluding In situ cases

Excluding cases of non-residents of the Cyprus Government Controlled Area

Including cases identified by Death Certificates Only


Number of C33-C34 (Trachea, Bronchus and Lung) Cancer Cases by histology and sex, 1998-2015*																			
ICDO3 Histology	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	Total
Adenocarcinoma, NOS	52	56	66	65	60	60	39	51	58	77	96	104	101	121	126	158	150	146	1586
Squamous cell carcinoma, NOS	26	31	29	35	23	29	36	35	35	30	41	45	40	54	56	51	64	73	733
Neoplasm, malignant	12	17	23	34	35	14	25	37	38	31	44	31	44	42	33	34	40	34	568
Small cell carcinoma, NOS	8	13	8	5	18	15	18	23	20	19	27	39	38	41	40	39	27	38	436
Non-small cell carcinoma				14	14	26	54	24	21	21	15	18	17	16	12	4	7	4	267
Bronchiolo-alveolar adenocarcinoma, NOS	1	4	2	8	4	6	7	5	9	10	5	5	3	3	6	9	3	4	94
Carcinoid tumor, NOS	3	1	1		2				3	2	3	3	4	3		6	2	3	36
Neuroendocrine carcinoma, NOS	1	1		2	1			2	2	2	4	1	2	3	2	3	8	1	35
Carcinoma, NOS	1	3	8	1	2	3	1					5		3	1	2	1	2	33
Oat cell carcinoma	1	2	2	2	7	3	5	5	1	1	2								31
Bronchiolo-alveolar carcinoma, mucinous					1		1		1	3	1	1	2	2		3	5		20
Squamous cell carcinoma, keratinizing, NOS	1	1		1	2		1		1	1			1	4	1	2	1	1	18
Large cell neuroendocrine carcinoma									1	1	1	6		3		1	2		15
Squamous cell carcinoma, large cell, nonkeratinizing, NOS				1					1			2	1	1		4	1	3	14
Large cell carcinoma, NOS	1					2				2	3	2	1			3			14
Carcinoma, undifferentiated, NOS	1	1	2	2	2				1	1	1				1				12
A typical carcinoid tumor													2	1	1	3	1	4	12
Papillary carcinoma, NOS				1		1		1				1		1	2	1	3		11
Bronchiolo-alveolar carcinoma, non- mucinous									1			3	1	3		2			10
Pseudosarcomatous carcinoma										1	1		1	3	2	1	1		10
Mucinous adenocarcinoma					1		1				1		1			1	1	4	10
Acinar cell carcinoma												2	3	1		2		1	9
Alveolar adenocarcinoma		3	1		1				2				1						8
Adenosquamous carcinoma					1					1			3			1			6
Clear cell adenocarcinoma, NOS				1		1			1			1	1	1					6
Small cell carcinoma, intermediate cell					1					1	2					1			5
Signet ring cell carcinoma							1	1				2		1					5
Sarcoma, NOS										1	1			1	1				4
Carcinosarcoma, NOS													1			1		1	4
Adenoid cystic carcinoma								1				1		1	1				4
Giant cell carcinoma	1		1					1				1							4
Papillary adenocarcinoma, NOS												1	1					1	3
Mucoepidermoid carcinoma						1						1	1						3
Basaloid squamous cell carcinoma										1			1				1		3
Lymphoepithelial carcinoma											1		1				1		3
Squamous cell carcinoma, small cell, nonkeratinizing																		2	2
Carcinoma, anaplastic, NOS							1	1											2
Mucin-producing adenocarcinoma														1				1	2
Neurilemoma, malignant					1														1
Peripheral neuroectodermal tumor			1										1						1
Spindle cell carcinoma, NOS																			1
Pleomorphic carcinoma									1										1
Small cell carcinoma, fusiform cell		1																	1
Pleuropulmonary blastoma											1								1
Combined small cell carcinoma				1															1
Adenocarcinoma with mixed subtypes										1									1
Fibromyxosarcoma																		1	1
Giant cell and spindle cell carcinoma														1					1
Papillary squamous cell carcinoma													1						1
Glassy cell carcinoma											1								1
Squamous cell carcinoma, spindle cell																1			1
Malignant tumor, giant cell type						1													1
Mixed cell adenocarcinoma															1				1
Total	109	134	144	173	177	161	189	188	197	208	250	280	270	311	287	332	319	324	4053

*Excluding In situ cases

Excluding cases of non-residents of the Cyprus Government Controlled Area
Including cases identified by Death Certificates Only



Time Trends in Crude Incidence Rate (Crude IR) and Age Standardised Incidence Rates (ASRW) for C33-C34 (Trachea, Bronchus and Lung), per 100 000*																		
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Crude IR	16.0	19.4	20.6	24.5	24.8	22.3	25.8	25.3	26.0	26.8	31.4	34.2	32.2	36.1	33.1	38.7	37.7	38.2
ASRW	11.7	14.4	15.3	16.7	16.7	14.2	16.8	16.1	17.0	17.7	20.0	21.2	19.9	21.7	19.9	23.0	21.0	20.9



*Excluding In situ cases
Excluding cases of non-residents of the Cyprus Government Controlled Area
Including cases identified by Death Certificates Only

DEFINITIONS:

Crude Incidence Rate : A crude (unadjusted) rate is calculated by dividing the number of new cancers observed during a given time period by the corresponding number of persons in the population at risk. The result is usually expressed a rate per 100,000 persons at risk.

ASR (age-standardized rate): An age-standardized rate (ASR) is a summary measure of the rate that a given population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are given by population distribution of a standard population. The most frequently used standard population is the World Standard Population. The calculated incidence rate is then called age-standardized incidence rate (world). It is also expressed per 100,000.